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Recent progress with specific markers of lymphatic vessel
endothelium allowed recognition of lymphangiogenic events
in various disease states; however, there is little information
concerning this process in human chronic renal diseases. To
determine this we measured expression of the lymphatic
marker D2-40 and vascular endothelial growth factor-C
(VEGF-C), a major growth factor in lymphangiogenesis, in 124
human renal biopsy specimens. In the kidneys of control
subjects and in uninjured areas of pathologic specimens,
lymphatic vessels were detected only around the arcuate and
interlobular arteries. An increase in the number of lymphatic
vessels was found at the site of tubulointerstitial lesions
correlating with the degree of tissue damage and more
strongly correlating with areas of fibrosis than inflammation.
On serial sections, lymphatic vessel proliferation was found in
the tubulointerstitial area at the site of tuft adhesions to
Bowman’s capsule. Lymphatic growth was associated with
VEGF-C expression in inflammatory mononuclear cells and
tubular epithelial cells, mainly of proximal tubules.
Lymphangiogenesis and VEGF-C expression was elevated in
diabetic nephropathy in comparison to other renal diseases.
Our results indicate that lymphangiogenesis is a common
feature in the progression of the tubulointerstitial fibrosis.
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Most commonly used endothelial markers, such as CD31,
CD34, and von Willebrand factor, are non-discriminatory and
are expressed by lymphatic endothelial cells.1 Therefore, the
distribution of capillaries derived from the blood system and
those of lymphatic origin is not clearly recognized owing to the
absence of specific markers. Several markers that are exclusively,
or at least predominantly, expressed by lymphatic endothelial
cells were recently discovered, including the tyrosine kinase
receptor for vascular endothelial growth factor receptor-3
(VEGFR-3), lymphatic endothelial hyaluronan receptor-1,
podoplanin, the transcription factor Prox-1, and D2-40.1–6
D2-40 is a novel monoclonal antibody against a 40 000-Da
O-linked sialoglycoprotein that reacts with a fixation-resistant
epitope on lymphatic vessels.7 An antibody against D2-40 has
been shown to detect lymphatic endothelium in formalin-fixed
tissues and does not react with the blood vessel endothelium.
These new markers of lymphatics enable one to identify
neoplastic cells in the Kaposi sarcoma and recognize newly
formed lymphatic vessels under diseased conditions.4,8–13
In the majority of organs, the lymphatic network is
responsible for the removal of interstitial protein and fluid,
thereby maintaining interstitial fluid balance and providing
lymphatic clearance of macromolecules. Under physiological
conditions, lymphatic vasculature is a rather quiescent
system; however, several pathological conditions, including
lymphatic vessel injury, inflammation, and cancer, are
characterized by lymphatic vessel growth through stimulation
by various growth factors. Lymphatic vessels provide key
routes for drainage of interstitial fluid from tissues. In
lymphangiogenesis, increased attention has been focused on
the VEGF-C–VEGF3R system as a potentially important
mediator.14–16 Gene transfer of VEGF-C resolved lymphede-
ma through direct augmentation of lymphangiogenesis,
whereas overexpression of VEGF-C or -D by gene transfer
ameliorated lymph and inflammatory tissue edema in animal
models of chronic airway inflammation, diabetic wound
healing, and metastatic cancer.9,17–19 In addition to its role in
fluid drainage, the lymphatic system also plays an important
role in circulating immune surveillance and for metastatic
dissemination of tumor cells through preexisting and
possibly through newly formed lymphatic vessels.20,21
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Recently, Kerjaschki et al.5 showed lymphatic neoangio-
genesis in renal transplants. However, the state of lymphatics
in chronic renal diseases is unknown. In this study, we
investigate the expression of D2-40-positive lymphatic vessels
and VEGF-C, the most important mediator of lymphangio-
genesis, in human renal diseases, and discuss the role of
newly formed lymphatics.
RESULTS
Lymphatic vessels in control kidney tissues
Peritubular capillaries and glomerular endothelial cells were
positive for CD31 in the normal structure of the renal cortex
(Figure 1a and c). However, D2-40-positive lymphatic vessels
were infrequently encountered in the normal cortical
tubulointerstitial area (Figure 1b and d), and were restricted
to the periarterial adventitia of large and intermediate-sized
arteries. As shown in Figure 1d, D2-40-positive lymphatic
vessels were detected adjacent to larger intrarenal branches of
the renal artery to the level of the arcuate artery. Lymphatic
endothelial cells positive for D2-40 were sometimes positive
for CD31 (Figure 1e and f), which is consistent with previous
reports that CD31 is not a specific marker for vascular
endothelial cells.8
Lymphatic vessels proliferated tubulointerstitial fibrosis
Lymphatic vessels in renal diseases. Increases in D2-40-
positive lymphatics in tubulointerstitial injury are generally
associated with glomerulonephritis and diabetic nephropathy
(Figures 1g–k, 2 and 4). The uninjured areas of renal cortical
interstitial tissues were universally indistinguishable from the
interstitial patterns of sparse lymphatics, as described above
in the control kidney. In the case of minimal change
nephrotic syndrome, immunoglobin A nephropathy (IgAN),
and focal glomerulosclerosis without interstitial fibrosis, D2-
40-positive lymphatic endothelial cells were rare in the
tubulointerstitial area (grade 0, Figure 4b). In contrast,
increased lymphatics were identified within injured tubu-
lointerstitial areas in IgAN, FGS, type 2 diabetic nephropathy,
tubulointerstitial nephritis (TIN), lupus nephritis, and anti-
neutrophil cytoplasmic antibody-related glomerulonephritis
(grade II and III, Figure 4a and b). Lymphatic endothelial
cells were detected in tubulointerstitial fibrotic lesions
(Figure 1g–j) and also in the interstitial area with numerous
infiltrating cells (Figure 1k). Small lymphatic vessels are
frequently filled with inflammatory cells in various renal
diseases. Interestingly, there is much less proliferation of
lymphatics in acute TIN than in chronic TIN (Figure 2b). In
periglomerular fibrotic lesions, lymphatic vessels were often
detected in diabetic nephropathy but not in non-diabetic
glomerular diseases (Figure 1e and f). A significant correla-
tion between the extent of tubulointerstitial fibrosis and the
number of lymphatics per surface area was observed
(Figure 2). Although there was a good correlation between
the increase in lymphatic growth and a-smooth muscle actin
(a-SMA)-positive fibroblasts and CD68-positive macro-
phages in the group of glomerular diseases other than
Co
nt
ro
l
Co
nt
ro
l
D
ia
be
tic
 N
D
ia
be
tic
 N
D
ia
be
tic
 N
lg
A 
N
Figure 1 | Distribution of lymphatic vessels in control and
diseased kidneys. D2-40-positive lymphatic vessels were rarely
detected in the normal architecture of the cortical
tubulointerstitial area (a, b). Lymphatics were observed around
the arcuate artery in control kidneys (c, d). D2-40-positive
lymphatic endothelial cells were sometimes positive for CD31
(e, f). Arrows indicate the same lymphatic vessels. Lymphatics
proliferated in tubulointerstitial fibrosis and areas with interstitial
infiltration (h, j, k). Clusters of inflammatory cells were observed in
D2-40-positive vasculature (inset, k). Immunohistochemistry for
CD31 (a, c, e), D2-40 (b, d, f, h, j, k), and Masson-Trichrome stain
(g, i) on serial sections. Control kidney (a–d), diabetic nephropathy
(e, f, i, j, k), IgA nephropathy (g, h). Bars¼ 100mm.
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diabetic nephropathy, no significant association was seen in
DMN. The number of lymphatic vessels also showed a
stronger correlation with a-SMA-positive fibroblasts than
with macrophages in glomerular diseases other than diabetic
nephropathy and TIN (Figure 3).
Lymphatic vessel proliferation was prominent in diabetic
nephropathy. The number of lymphatics was significantly
higher in diabetic nephropathy, particularly with mild-to-
moderate levels of tubulointerstitial fibrosis (grade I
(Po0.0001) and II (Po0.05)), as compared with the same
extent of tubulointerstitial injury in non-diabetic renal
diseases (Figure 4a). When we compared the number and
extension of lymphatic vessels in DMN against those in other
renal diseases, lymphatics were significantly increased in
DMN specimens, particularly when compared with IgAN
(grade I (Po0.005) and II (Po0.05)), and TIN (grade III
(Po0.05) (Figure 4b)).
Lymphatic vessels grew in inflammatory interstitium and
interstitial fibrosis induced by misdirected filtration. To explore
the possible roles of proliferation of the lymphatic vessel
system in the tubulointerstitial area, we immunohistochemi-
cally examined the presence of D2-40 on sequential sections.
Lymphatic growth was observed to transmigrate into the
interstitial area accompanied by infiltration of mononuclear
cells (Figure 5). The lumens of lymphatic vessels were
frequently occupied by mononuclear cells in a high-power
field on light microscopy (Figures 1k and 5). Lymphatic
vessels with peripheral extension were confirmed to contact
the trunk stream of the lymphatics adjacent to the
interlobular arteries on serial sections (Figure 5).
In 10 out of 38 cases of IgAN and in 4 out of 20 case of
DMN, we found tubular degeneration and interstitial fibrosis
induced by misdirected filtration in glomerular injury with
tuft adherence. Urinary fluid can be filtrated into the
interstitium at tuft adherences to Bowman’s capsule (Figure 6,
arrow heads in panels c and d, arrow in panel e). An analysis
of serial sections in these cases confirmed numerous
lymphatics in these areas. These networks might function
to drain the misdirected filtrated fluid into the tubulointer-
stitial area (Figure 6). In these biopsy specimens, the
distribution of lymphatic vessels was restricted around the
affected nephron (Figure 6a and b, arrows).
In DMN, lymphatic vessels were often detected around the
glomerulus in association with fibrotic changes (Figures 1e, f
and 7). In these glomeruli, the glomerular tuft connects to
the periglomerular interstitium through a gap in Bowman’s
capsule (arrow in Figure 7, serial section numbers 7–11).
Misdirected urinary filtration into the periglomerular space
appears to enhance periglomerular fibrosis and lymphangio-
genesis. These lymphatics were connected to the trunks
(Figure 7). In some glomeruli in diabetic kidneys, lymphatic
vessels were detected in the surroundings of the glomerulus
without periglomerular fibrosis (Figure 1e and f). In contrast,
these findings were not seen in non-diabetic renal diseases,
including IgAN.
Expression of VEGF-C in tubulointerstitial area
VEGF-C expression is accompanied by lymphatic proliferation
in tubulointerstitial fibrosis. In the normal control kidney,
VEGF-C was weakly detected in tubular epithelial cells.
In the tubulointerstitial area with tissue injuries, VEGF-C
was expressed by interstitial mononuclear cells and was
upregulated in tubular epithelial cells in association
with the proliferation of lymphatic vessels. More than 80%
of the VEGF-C expressing mononuclear cells were CD68
positive. VEGF-C was detected in the proximal tubules and in
some parts of the collecting tubules in the injured
tubulointerstitial area (Figure 8i–k). The VEGF-C expression
score was higher in DMN (tubulointerstitial injury score,
2.17±0.18) than in IgAN (tubulointerstitial injury score,
2.14±0.15), with the same extent of tubulointerstitial
damage (VEGF-C expression score, 2.59±0.12 vs
1.52±0.19, Figure 9).
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Figure 2 | Relationship between the number of lymphatic
vessels and the extent of tubulointerstitial lesions. (a) Grading
of interstitial fibrosis (0 to III) was assessed by image analysis. (b)
Acute and chronic tubulointerstitial nephritis. **Po0.005,
##Po0.001, ###Po0.0001.
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Expression of VEGF-C in proximal tubular epithelial cells
To clarify the expression of VEGF-C by proximal tubular
epithelial cells, we explored the expression of VEGF-C
in rat proximal tubular epithelial cells harvested by Laser
capture microdissection and in two human proximal
tubular epithelial cell lines (Figure 10). VEGF-C mRNA
and 18S rRNA were seen in normal rat proximal tubular
epithelial cells. In cultured proximal tubular epithelial
cells and PC-3 cells (prostate adenocarcinomas as a
positive control), PCR products of VEGF-C and glyceralde-
hydes-3-phosphate dehydrogenase were detected, but
no PCR product was yielded in the absence of cDNA
(data not shown). enzyme-linked immunosorbent assay
showed that VEGF-C protein was secreted into the super-
natants by both HK-2 and RPTEC under serum-free
conditions.
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Figure 3 | Correlation between lymphangiogenesis and expression of a-smooth muscle actin (a-SMA)-positive fibroblasts and CD68-
positive macrophages. (a, b) Glomerular diseases other than diabetic nephropathy. (c, d) Diabetic nephropathy. (e, f) Tubulointerstitial
nephritis. (a, c, e) a-SMA. (b, d, f) CD68.
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DISCUSSION
Blood vessels have a continuous basal lamina with tight inter-
endothelial junctions, and are supported by pericytes and
smooth muscle cells. In contrast, lymphatic endothelial cells
have a discontinuous basal lamina and have gaps between the
lymphatic endothelial cells that can open into the adjacent
connective tissues. In edematous tissue, the endothelial cells
of lymphatics are pulled by anchoring filaments and bileaflet
valves to prevent the backflow of lymphatic fluid.16 These
structures are fit to remove tissue fluid from interstitium, and
to transfer extravasated plasma protein and cells back into
circulation. Recently, increases in lymphatic vessels have been
reported in several conditions, including tumor metastasis,22
respiratory inflammatory diseases,18 wound healing,23 and
granulation tissues in myocardial infarction.8 In the renal
transplant rejection, lymphatic neoangiogenesis was seen as
early as 72 h after transplantation.24 In the transplanted
kidney, lymphatic neo-angiogenesis was closely associated
with inflammatory infiltrates and was correlated to allograft
function at 1 year after transplantation.5,25 These reports
suggested that lymphatic vessel proliferation in the cortex of a
renal allograft may alter immune response to the graft,
possibly owing to the attenuation of pathogenicity of cellular
infiltrates.25 Under these physiological and the pathological
conditions, inflammation and the accompanying fluid over-
load are considered to stimulate lymphangiogenic response.
Here, we investigated the expression of lymphatics in
human renal diseases. In the normal kidney, lymphatic
vessels are found only around interlobular and arcuate
arteries, whereas in cortical areas without tubulointerstitial
injury, lymph vessels are rarely observed. However, in
tubulointerstitial fibrosis and inflammatory interstitial areas,
lymphatic vessels proliferated and were often found to be
filled with mononuclear cells in the lymphatic lumen. We
showed that the extent of lymphatic growth was significantly
correlated with tubulointerstitial injury. Fibrosis is the final
common pathway for almost all forms of renal disease that
progress to end-stage renal failure, including immunologi-
cally mediated glomerulonephritis and TIN, hemodynamic
and metabolic disorders, and hereditary diseases. Fibrosis is
often accompanied by infiltration of inflammatory cells and
tubular damage, which plays a role in accelerating the
progression of interstitial fibrosis by production and secre-
tion of cytokines and growth factors.26 Lymphatic vessels
have been shown to expand into the tubulointerstitial area
with accumulation of mononuclear cells and/or with tubular
atrophy and degeneration in chronic renal diseases. Although
lymphatic vessels were grown in chronic TIN, lymphangio-
genesis was not prominent in acute TIN, as recently reported
by Heller et al.27 This suggests that chronic inflammation
may trigger lymphangiogenesis. Kriz et al.28–31 used several
animal models and human studies to establish that
misdirected filtration of the tubulointerstitium in glomerular
injury with tuft adherence is an important pathway that leads
to tubular degeneration and interstitial fibrosis. In the
context of focal and segmental glomerulosclerosis (FSGS),
misdirected filtration and peritubular filtrate spread may
extend injury to the corresponding tubulointerstitium, thus
leading to severely injured nephrons.28–31 However, the final
process of overflow by misdirected filtration is uncertain. We
observed that lymphatic vessel density increased markedly in
the tubulointerstitial area, where urine is filtrated in the
wrong direction and inflammatory cells infiltrate. We also
found that the lymphatic network developed around the
glomerulus, with the paraglomerular and paratubular space
filled with extracellular matrix. On the basis of recent reports
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Figure 4 | Difference in lymphatic proliferation between
diabetic and non-diabetic renal diseases. (a) Lymphatic growth
in diabetic nephropathy was higher than in non-diabetic renal
diseases in grade I and II tubulointerstitial fibrosis. Statistical
analysis was performed against the same grade of diabetic
nephropathy. (b) Extent of lymphatic proliferation was higher in
diabetic nephropathy than in IgA nephropathy (grade I (Po0.005)
and II (Po0.05)) and tubulointerstitial nephritis (grade III
(Po0.05)). *Po0.05, **Po0.005, #Po0.01, ###Po0.0001, NS, not
significant; ND, statistical analysis was not performed owing to the
small number of patient samples; N, none of the cases in these
groups.
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of the possible role of lymphangiogenesis in diseased
conditions, our findings suggest that filtered fluid and
inflammatory cells may stimulate local lymphangiogenesis,
and might be eliminated through proliferated lymphatics in
chronic renal diseases. Lymphangiogenesis was correlated
more strongly with a-SMA-positive expression than with
infiltration of CD68-positive cells. In addition, growth of the
lymphatic vessels was not prominent in acute TIN. Our
observations suggest that lymphangiogenesis is affected by
the duration of inflammation and progression of fibrosis,
rather than by acute inflammation. It is noted that the extent
of lymphangiogenesis with VEGF-C expression was higher in
DMN than in other renal diseases. Furthermore, no
correlation was seen between lymphatic growth, fibrosis,
and infiltration in DMN. These results suggest that diabetic
conditions, such as high glucose and AGE, may be related to
the higher growth of lymphatics in DMN.
Vascular endothelial growth factor-C and -D, members of
the VEGF family of polypeptide growth factors, drive
lymphangiogenesis through VEGF receptor-3 (VEGFR-3,
known as Flt4) signaling and partly through VEGFR-2
(Flk-1).15 VEGF-D, as well as VEGF-C, appears to induce
angiogenesis through VEGFR-2. Other mediators, such as
VEGF-A and PDGF, may induce lymphatic growth under
certain conditions.32–34 Of these, the VEGFC-VEGF3R system
has been considered to be the main signaling pathway to
induce lymphangiogenesis.14–16 In our analysis, lymphangio-
genesis was found to be associated with VEGF-C expression
in human renal biopsy specimens. VEGF-C was expressed
by inflammatory CD68 positive mononuclear cells as
reported.21,22 In addition, we found a strong expression of
VEGF-C in the tubular epithelial cells, and that proximal
tubules are one of the important sources of VEGF-C in renal
diseases. Expression of VEGF-C by tubular epithelial cells
may contribute to lymphangiogenesis, which shows a
stronger correlation with fibrosis than inflammation. Stimu-
lation of lymphatic growth was recently considered as a
possible new target in some disease states. The relative
importance of lymphangiogenesis will have to be established
by manipulation of VEGF-C or -D levels in chronic renal
injury models.
There have been some reports showing increased angio-
genesis in DMN.35–37 Nevertheless, the role of VEGF-C in
DMN has not yet been studied in detail. VEGFR-2, which is
G
A
G
Figure 5 | Immunohistochemistry for D2-40 on serial sections of tubulointerstitial inflammation in patients with diabetic
nephropathy. Scheme indicates that proliferated lymphatic vessels transmigrate into the interstitial mononuclear cell–infiltrated area.
G: glomerulus, A: interlobular artery, Red, blue, and black arrows indicate the connection between lymphatic branches. Bars¼ 100mm.
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one of the ligands for VEGF-C and stimulates vascular
endothelial growth and angiogenesis, was shown to be
elevated in streptozotocin-induced diabetic kidney.14–16,38
Upregulation of VEGF-C may be linked with both lymphan-
giogenesis and dysregulated blood vessel endothelial cell
proliferation in DMN. Furthermore, the extent of lymphan-
giogenesis and VEGF-C expression was higher in DMN.
Future studies are necessary to investigate the regulation and
interaction between VEGF-C, and lymph and vascular
neoangiogenesis under diabetic conditions in animal and
culture experiments.
In summary, we showed that lymphatic vessels proliferate
and show good correlation with tubulointerstitial injury in
chronic renal diseases. Inflammatory mononuclear cells and
interstitial fluid, particularly owing to misdirected filtration,
may trigger regional lymphatic angiogenesis, which leads to
their transport. The clinical impact of local increases of
lymphatic vessels in the tubulointerstitial area remains
uncertain. Further enhancement of VEGF-C expression and
lymphangiogenesis, and their role in chronic renal diseases
and in DMN, will have to be established in the future.
MATERIALS AND METHODS
Patient profiles and histological stratification
A total of 121 specimens from control (n¼ 9) and human diseased
kidneys (n¼ 115) were studied (Table 1). Kidney specimens were
obtained from patients undergoing diagnostic evaluation at Nagoya
University Hospital (Nagoya, Japan). Biopsy kidney specimens taken
1 h after renal transplantation were used as controls. Histological
diagnoses are listed in Table 1. These include minimal change
nephrotic syndrome, IgAN, DMN, focal glomerulosclerosis, lupus
nephritis, anti-neutrophil cytoplasmic antibody-related glomerulo-
nephritis, TIN, and other renal diseases. All cases of acute TIN were
drug-induced TIN, and chronic TIN was mainly because of
Scho¨gren’s syndrome. The mean duration from initiation of
symptoms to renal biopsy of acute and chronic TIN was 0.9±0.2
and 31.4±18.7 months, respectively. Histological diagnosis was
performed by light microscopy, immunofluorescence microscopy,
and electron microscopy. Six representative serial sections for DMN
(n¼ 3) and IgAN (n¼ 3) were subjected to immunohistochemistry,
and were carefully examined to explore the role of lymphatic vessel
development in the tubulointerstitial area.
Figure 6 | Immunohistochemistry for D2-40 on serial sections
in patient with IgA nephropathy. Lymphatic vessels were
detected in an area showing misdirected filtration of urine. Series
of sections from a nephron with segmental glomerulosclerosis.
Only tubulointerstitial fibrosis was detected around the segmental
sclerotic glomeruli in this specimen (a, b, arrow). D2-40-positive
lymphatic vessels were seen only in these areas (a, b, arrow). Tuft
adhesion to Bowman’s capsule, where filtered urine may pass, is
present (arrowhead in c, d; arrow in e). Sclerotic tuft portion with
hyaline deposition protrudes through the gap of Bowman’s
capsule. *Proximal tubule appears obstructed. Masson–Trichrome
stain (a, c), PAM stain (e) and D2-40 stain (b, d). Bars¼ 100 mm.
Table 1 | Renal biopsy cases evaluated for lymphatic vessels
Number Gender M/F Age Hypertension Proteinuria (g/day) eGFR (ml/min)
Control 9 6/3 37±5.0 — — —
Minimal change nephrotic syndrome 10 9/1 44.5±6.0 4/10 4.9±1.5 60.0±6.9
IgA nephropathy 38 27/11 45.2±3.0 20/38 2.5±0.5 48.3±3.6
DMN 20 16/4 60.7±3.0 14/20 5.8±1.1 41.4±5.8
Nephrosclerosis 8 8/0 44.5±6.3 8/8 1.6±0.4 28.8±2.7
TIN 16 10/6 52.7±5.5 7/16 0.49±0.11 23.2±3.7
Acute TIN 7 5/2 40.6±9.2 3/7 0.43±0.13 27.5±7.2
Chronic TIN 9 5/4 62.1±5.1 4/9 0.50±0.16 18.2±2.9
Focal and segmental glomerulosclerosis 4 3/1 61.5±6.7 3/4 4.3±2.9 42.1±14.2
Lupus nephritis 3 1/2 34.7±4.2 0/3 6.0±3.9 57.2±26.8
ANCA-related glomerulonephritis 3 1/2 70.3±9.4 3/3 1.7±1.2 9.5±4.1
Others 13 9/4 44.8±5.6 8/13 3.2±1.0 27.9±6.7
Total 124 Means±s.e.
ANCA, anti-neutrophil cytoplasmic antibody; DMN, type 2 diabetic nephropathy; eGFR, endothelial growth factor receptor; IgA, immunoglobin A; TIN, tubulointerstitial
nephritis.
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Histology and immunohistochemistry
Formalin-fixed paraffin sections were deparaffinized with xylene,
rehydrated, and washed with phosphate-buffered saline. After
blocking endogenous peroxidase activity with 0.3% hydrogen
peroxide and free protein-binding sites with normal goat serum
(Dako, Glostrup, Denmark), tissues were incubated with primary
murine monoclonal antibodies against D2-40 (Dako), a-SMA (1A4;
Dako), CD68 (PG-M1; Dako), and CD31 (Dako) for 2 h at room
temperature. After washing with phosphate-buffered saline, the
sections were treated with a conjugate of polyclonal goat anti-rabbit
IgG antibodies or anti-mouse IgG antibodies, and with horseradish
peroxidase-labeled polymer (Histofine Simple Stain, Nichirei,
Tokyo, Japan) as secondary reagents. Enzyme activity was finally
a
A g
Figure 7 | Immunohistochemistry for D2-40 on serial sections
from patient with diabetic nephropathy. D2-40-positive
lymphatic vessels are present around the glomerulus with
periglomerular fibrosis. Glomerulus (g) with tuft adhesion to
Bowman’s capsule (arrow) is associated with thick paraglomerular
and paratubular space filled with matrix (indicated by open
arrowhead, serial section numbers 7–26). Urinary orifice is
narrowed by these spaces. Scheme indicates that the lymphatic
vessel system connects to the lymphatic trunk. A, a: interlobular
artery, g: glomerulus, *: urinary pole. Bars¼ 100 mm.
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Figure 8 | Expression of vascular endothelial growth factor C
(VEGF-C) and D2-40-positive lymphatic vessels in
tubulointerstitial lesions on serial sections. VEGF-C is
expressed in the proximal tubules (arrowhead) and in some parts
of the collecting tubules (*) in the injured tubulointerstitial area.
VEGF-C is negative in some parts of the proximal tubules (arrow).
(a, c, e, g) D2-40 staining. (b, d, f, h, k) VEGF-C staining. (i)
Aquaporin 1 staining. (j) Aquaporin 2 staining. (a, b) Control
kidney. (c, d, g, h, i, j, k) Diabetic nephropathy. (e, f) IgA
nephropathy. gl: glomerulus, GL: another glomerulus,
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detected using a 3,30-diaminobenzidine tetrahydrochloride liquid
system (Dako).39,40 Immunohistochemistry for VEGF-C was
performed on frozen sections in 53 cases, including 9 controls, 17
cases of DMN, and 27 cases of IgAN. The sections (4mm) were cut
with a cryostat, air-dried, and fixed in acetone at room temperature
for 10 min. Endogenous peroxidase activity was inhibited with 0.1%
NaN3 and 0.3% hydrogen peroxide in phosphate-buffered saline,
and nonspecific protein-binding sites were blocked with normal
goat serum. The sections were incubated with rabbit anti-VEGF-C
antibody (Zymed Laboratories, South San Francisco, CA, USA) or
anti-D2-40 antibody, followed by a conjugate of anti-rabbit IgG
antibodies, and with horseradish peroxidase-labeled polymer
(Histofine Simple Stain, Nichirei) as secondary reagent. Enzyme
activity was detected by 3-amino-9-ethyl-carbazole (Dako).39,40 To
identify the tubular segments expressing VEGF-C in the diseased
kidney, serial sections were stained with rabbit anti-Aquaporin 1
(marker of proximal tubules, Chemicon, Temucula, CA, USA) and
rabbit anti-Aquaporin 2 (marker of collecting duct, Calbiochem,
Darmstadt, Germany), as described previously.41
Correlation between number of lymphatic vessels and
tubulointerstitial injury
To assess the correlation between the number of interstitial
lymphatic vessels and tubulointerstitial injury, D2-40-positive
vessels, CD68-positive macrophages, and VEGF-C-positive cells
were identified and counted in the whole cortex of biopsy specimens
using Zeiss Z1 image microscopy and Axiovision Windows software,
version 4.4 (Carl Zeiss, Oberkochen, Germany). Lymphatic vessel
density in the whole cortical area was calculated and was expressed
as lymphatic vessel density per square millimeter (/mm2).
Lymphatic vessels in the vicinity of interlobular arteries were not
taken into account, as they were considered to be physiologically
present in the normal kidney cortex.42 Tubulointerstitial injury was
assessed as a percentage of blue stained area on Masson-trichrome
staining, and was measured using MetaMorph 6.3 image analysis
software (Universal Imaging Co., West Chester, PA, USA), followed
by classification into four groups according to the extent of cortical
interstitial fibrosis, and tubular atrophy and degeneration: (0)
normal; (I) mild interstitial fibrosis and tubular atrophy (o25% of
cortical area); (II) moderate interstitial fibrosis and tubular atrophy
(26–50% of cortical area); (III) severe interstitial fibrosis and tubular
atrophy/loss (450% of cortical area). This is comparable with the
chronic changes score in the Banff classification of kidney transplant
pathology.43 VEGF-C expression in the tubulointerstitial area was
analyzed and semiquantitatively classified into four groups by
positive staining area: (0) no staining; (1) mild; (2) moderate; (3)
pronounced staining. The a-SMA positive area was also assessed
using MetaMorph 6.3 image analysis software.
Laser capture microdissection using normal rat kidney
Seven-week-old male Sprague Dawley rats (Japan SLC, Hamamatsu,
Japan) were used. Frozen tissues were sectioned at 8 mm and
mounted on glass slides using the RNase-free technique. The tissues
were stained with an Ambion LCM (laser capture microdissection)
Staining kit (Ambion, Austin, TX, USA) and stored until
microdissection. Regions of proximal tubular epithelial cells were
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Figure 9 | Expression of vascular endothelial growth factor C
(VEGF-C) score in diabetic nephropathy and IgA nephropathy.
VEGF-C expression score is higher in diabetic nephropathy than in
IgA nephropathy. ##Po0.001, ###Po 0.0001.
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Figure 10 | Expression of vascular endothelial growth factor C
(VEGF-C) in the proximal tubular epithelial cells. (a) Rat
proximal tubular epithelial cells harvested by laser capture
microdissection. VEGF-C mRNA and 18S rRNA were detected. (b)
Cultured human proximal tubular epithelial cells, HK-2 and RPTEC.
VEGF-C mRNA and glyceraldehydes-3-phosphate dehydrogenase
(GAPDH) were detected. (c) VEGF-C protein was detected in the
supernatants of HK-2 and RPTEC. Medium contains Dulbecco’s
Modified Eagle’s Medium and Ham’s F-12.
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dissected using the MB III System (PALM, Bernried, Germany), and
were captured with PALM AdhesiveCaps 500 clear (PALM).
Cell culture study
Two human proximal tubular cell lines, HK-2 and RPTEC, were
purchased from the American Type Culture Collection (ATCC,
Manassas, VA, USA) and Takara Bio (Ohtsu, Shiga, Japan),
respectively, and were maintained according to the manufacturers’
guidelines. Briefly, HK-2 cells and RPTEC were grown in complete
medium containing Dulbecco’s Modified Eagle’s Medium and
Ham’s F-12 (Sigma, Tokyo, Japan) supplemented with 10% fetal
bovine serum (Hyclone, Logan, UT, USA) or 2% fetal bovine serum,
and hormones in humidified air with 5% CO2 at 371C, as described
previously.44 Under subconfluent conditions, both cells were washed
twice with phosphate-buffered saline, and the culture medium was
replaced with a serum-free medium for 16 h. PC-3 cells (ATCC)
derived from human prostate adenocarcinomas, which was reported
earlier to secrete VEGF-C into culture supernatants, were cultured
and used as positive controls for VEGF-C protein and mRNA
expression.45
RNA preparation
For proximal tubular cell lines, total RNA was extracted using the
RNeasy Mini Kit (Qiagen, Hilden, Germany). Total RNA concen-
trations were estimated using a spectrophotometer (Ultrospec 3300
pro, Amersham Biosciences, Tokyo, Japan). For laser captured cells,
RNA was isolated with RNeasy Micro Kits (Qiagen), and RNA
integrity was assessed using the Agilent 2100 Bioanalyzer (Agilent,
Santa Clara, CA, USA).46
Polymerase chain reaction
For cultured cells, first-strand cDNA was synthesized using the
Omniscript Reverse Transcription Kit (Qiagen), according to the
manufacturer’s instructions. PCR was performed using the Hot-
StarTaq PCR kit (Qiagen), as described previously.45 PCR products
for VEGF-C (865 bp) and glyceraldehydes-3-phosphate dehydro-
genase (188 bp) were electrophoresed on 2% agarose gels in Tris-
acetate EDTA buffer, followed by staining with ethidium bromide.
Synthetic oligonucletoides sense (50-AGTTTTGCCAATCACA
CTTCCTG-30) and antisense (50-GTCATTGGCAGAAAACCAG
TCTT-30), and sense (50-ATCATCCCTGCCTCTACTGG-30) and
antisense (50-CCCTCCGACGCCTGCTTCAC-30) were used as
specific primers for VEGF-C and glyceraldehydes-3-phosphate
dehydrogenase, respectively.45
For laser capture microdissected samples, cDNA was synthesized
with a Sensiscript RT Kit (Qiagen), preamplified by the TaqMan
PreAmp Master Mix Kit using the GeneAmp PCR System 9700,
and the TaqMan Gene Expression Assays for VEGF-C (assay
identification number Rn00586458_m1) and 18S ribosomal
RNA (4319413E), according to the manufacturer’s specifications
(Applied Biosystems Inc., Foster City, CA, USA). PCR analysis was
then performed with an Applied Biosystems Prism 7500HT
Sequence Detection System with the same primers. PCR products
for VEGF-C (115 bp) and 18S rRNA (187 bp) were then electro-
phoresed.
VEGF-C enzyme-linked immunosorbent assay
Secretion of VEGF-C into the cell culture supernatant was
determined using the Human VEGF-C Assay kit (IBL, Takasaki,
Japan), according to the manufacturer’s instructions.
Statistical analysis
Values are expressed as means±s.e. Comparisons among groups
were performed by one-way analysis of variance, followed by
Dunnett’s or Tukey’s HSD multiple comparison test. For statistical
analysis between DMN and non-diabetic diseases for lymphatic
vessel expression, the two-tailed Student’s t-test was performed. A
comparison between groups for VEGF-C expression score was
performed by the Mann–Whitney test. Differences were considered
to be statistically significant at Po0.05. All analyses were performed
using SPSS (Chicago, IL, USA).
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